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The endothelium plays a crucial role in inflammation. A balanced control of inflammation 
requires the action of glucocorticoids (GCs), steroidal hormones with potent cell-specific 
anti-inflammatory properties. Besides the classic anti-inflammatory effects of GCs on leu-
kocytes, recent studies confirm that endothelial cells also represent an important target 
for GCs. GCs regulate different aspects of endothelial physiology including expression 
of adhesion molecules, production of pro-inflammatory cytokines and chemokines, and 
maintenance of endothelial barrier integrity. However, the regulation of endothelial GC 
sensitivity remains incompletely understood. In this review, we specifically examine the 
endothelial response to GCs in various inflammatory diseases ranging from multiple scle-
rosis, stroke, sepsis, and vasculitis to atherosclerosis. Shedding more light on the cross 
talk between GCs and endothelium will help to improve existing therapeutic strategies 
and develop new therapies better tailored to the needs of patients.
Keywords: endothelium, glucocorticoids, glucocorticoid resistance, inflammation, cytokines, tight junctions, 
adhesion molecules
1. iNTRODUCTiON
Glucocorticoids (GCs) are endogenous stress hormones with strong anti-inflammatory properties. 
Therefore, GCs have been therapeutically exploited for more than six decades, often at dosages, 
which exceed the physiological levels (1). GCs influence the function of various subtypes of 
immune cells including T cells, dendritic cells, macrophages, and B cells (2). A growing amount of 
evidence indicates that GCs also regulate multiple aspects of endothelial physiology. In this review, 
we discuss the effects of GCs on endothelium and the mechanisms that control GC sensitivity in 
endothelial cells.
2. eNDOTHeLiAL CeLL BiOLOGY iN A NUTSHeLL
2.1. Morphology and Heterogeneity of the endothelium
The human body contains approximately 2.5 × 1012 endothelial cells that are typically flat with a thin 
basement membrane (also known as basal lamina) enriched in type IV collagen and laminin (3–5). 
However, in specific blood vessels used by lymphocytes to enter the lymph nodes (high endothelial 
venules) endothelial cells are plum and tall with thick basal lamina (6). The thickness of endothelium 
varies from 0.1 µm in capillaries and veins to 1 µm in the aorta (4).
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Endothelial cell phenotypes vary between different organs, 
between different segments of the vascular bed within the 
same organ, and between neighboring endothelial cells of 
the same organ and blood vessel type (7). In arteries and veins, the 
endothelium forms a continuous layer of cells held together by 
tight junctions (TJs)—one of the two main types of intercellular 
junctions in endothelium (7, 8). Endothelial cells in arteries are 
long and narrow and are aligned in the direction of blood flow. 
In contrast, in veins endothelial cells are wider and shorter and 
lack the alignment in the direction of blood flow (9). Capillary 
endothelial cells are highly adapted to underlying tissues and 
present many phenotypic differences between different vascular 
beds (9). The endothelium of capillaries may be continuous, 
fenestrated, or discontinuous (7). The microvascular bed of each 
organ is composed of specialized endothelial cells endowed with 
a unique set of adhesion molecules, chemokines, transcription 
factors, and metabolic profiles (10).
2.2. Functions of the endothelium
The endothelium participates not only in blood delivery but also 
in organ regeneration and maintenance of homeostasis (11). 
Endothelial cells are metabolically active and play an important 
role in physiological processes such as the control of vasomotor 
tone, the trafficking of leukocytes between blood and underlying 
tissue, angiogenesis, and both innate and adaptive immunity (7).
In the central nervous system (CNS), the endothelium forms 
the blood–brain barrier (BBB) that controls the exchange of 
immune cells and mediators between blood and CNS (12). The 
BBB consists of a thick glycocalyx, endothelial cells linked by 
tight junctions (TJs), a double basement membrane, and astro-
cytic end-feet (13). The double basement membrane enables 
precise localization of sites of immune cell extravasation (14). 
Endothelial TJs, which constitute a crucial element of the BBB, 
control paracellular movement of solutes through the BBB and 
maintain brain homeostasis. They consist of claudins, occludin, 
and junction adhesion molecules (JAMs) (15). TJs are intermin-
gled with adherens junctions (AJs) that form a belt via interaction 
between cadherins (8, 15). Proper organization of TJs requires 
AJs assembly (16).
2.3. endothelial Activation during 
inflammation and Angiogenesis
Although at rest endothelial cells present a non-reactive surface 
at the interface between blood and tissue, upon activation the 
endothelium becomes a major player in the generation of 
the inflammatory response (3). Pro-inflammatory cytokines 
produced by immune cells activate the endothelium and medi-
ate leukocyte recruitment. Endothelial selectins such as E- and 
P-selectin capture leukocytes from the blood flow and mediate 
rolling (17). This slows down the circulating leukocytes and 
enables chemokines, localized on the endothelial surface, to 
interact with their receptors on leukocytes leading to integrin 
activation (12). Pro-inflammatory mediators such as tumor 
necrosis factor (TNF), interleukin (IL)-1, -17A, -18, -33, -36γ, 
and interferon (IFN)-α, -β, -γ stimulate the endothelium to 
produce various chemokines including CC chemokine ligand 
2 (CCL2, also known as monocyte chemoattractant protein-1 
or MCP-1), CCL20 (also known as macrophage inflammatory 
protein-3α or MIP-3α), CXC chemokine ligand 1 (CXCL1, also 
known as growth-related oncogene-α or GRO-α), CXCL8 (also 
known as IL-8), CXCL9 (also known as monokine induced 
by IFN-γ or MIG), CXCL10 (also known as IFN-γ-induced 
protein-10 or IP-10), CXCL11 (also known as interferon-
inducible T cell α chemoattractant or I-TAC), and also integrin 
ligands such as intercellular cell adhesion molecule-1 (ICAM-1) 
and vascular cell adhesion molecule-1 (VCAM-1) (3, 18–24). In 
contrast, IL-10 and IL-37 decrease CXCL8 (IL-8) and ICAM-1 
expression in endothelial cells (25, 26). ICAM-1 and VCAM-1 
control firm adhesion and leukocyte crawling on the endothe-
lial surface until they transmigrate through the endothelial 
barrier (27). Platelet endothelial cell adhesion molecule-1 
(PECAM-1) controls localization of junctional proteins such as 
VE-cadherin and β-catenin and mediates leukocyte extravasation 
to the sites of inflammation (28).
Angiogenesis—the growth of new blood vessels—plays an 
important role in the control of embryonic development and 
is involved in various human diseases. Increased angiogenesis 
is associated with neoplastic diseases, while insufficient blood 
vessel growth limits the repair process in ischemic cardiovas-
cular diseases (29, 30). Vascular endothelial growth factor 
(VEGF) regulates vascular development during embryogen-
esis, blood vessel formation in adults, wound healing, and 
organ regeneration (31, 32). In mammals, five VEGF ligands 
(VEGF-A, -B, -C, -D, and placental growth factor—PLGF) can 
bind to three receptor tyrosine kinases—VEFG receptor-1, -2, 
and -3 (32). Binding of VEGF to its receptor also increases 
vascular permeability through activation of focal adhesion 
tyrosine kinase (FAK) that interacts with vascular endothelial 
cadherin (VE-cadherin) leading to VE-cadherin–β-catenin 
dissociation (33). The Tie receptors (Tie-1 and Tie-2) 
and their angiopoietin ligands (ANG1–ANG4) constitute 
the second receptor Tyr kinase system in the vasculature. 
ANG–Tie controls vessel quiescence and regulates later stages 
of angiogenesis (30). ANG1 exerts its anti-inflammatory 
effects through inhibition of VEGF-induced expression of 
ICAM-1, VCAM-1, and E-selectin (34). Moreover, ANG1 
prevents VEGF and TNF-induced expression of the pro-
coagulatory molecule tissue factor (TF) (35). Later, ANG2 was 
described as a ligand that antagonizes ANG1 activity on Tie-2 
and acts as a switch between the quiescent and inflamed state 
of endothelium (36, 37). ANG2 also controls later steps of leu-
kocyte adhesion. Furthermore, ANG2 sensitizes endothelial 
cells toward TNF and modulates TNF-induced expression of 
adhesion molecules (36).
Matrix metalloproteinases (MMPs) control turnover of 
the extracellular matrix and are crucial in the regulation of 
inflammation. MMPs regulate leukocyte recruitment and 
modulate cytokine and chemokine activity (38, 39). For 
example, MMP-9 induces endothelial barrier breakdown 
through degradation of endothelial junctions (40). MMP-9 
also plays an important role in matrix remodeling during 
angiogenesis and mediates influx of proteins into angiogenic 
tissue (41, 42).
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3. GLUCOCORTiCOiDS (GCs) AND THe 
GLUCOCORTiCOiD ReCePTOR (GR)
3.1. GCs as inhibitors of inflammation
Glucocorticoids (GCs) are steroidal hormones that are synthe-
sized in the zona fasciculata of the adrenal cortex, starting from 
a cholesterol scaffold (43, 44). GCs are produced in a circadian 
pattern or in response to stress and regulate various physi-
ological processes including metabolism of sugar, protein, fat, 
muscle and bone, cardiovascular function, reproduction, and 
cognition (45). The hypothalamo–pituitary axis controls the 
secretion of cortisol, which is the physiologically active human 
GC (46, 47). The periventricular nucleus of the hypothalamus 
produces corticotrophin-releasing hormone (CRH), which 
induces the synthesis of adrenocorticotropic hormone (ACTH, 
also called corticotrophin) in the anterior pituitary gland. ACTH 
subsequently induces the production of the active cortisol, which 
in turn inhibits the secretion of CRH in the hypothalamus via a 
negative feedback mechanism (45, 48, 49).
Importantly, GCs also act as strong anti-inflammatory media-
tors, providing a negative feedback on inflammation (50–52). The 
anti-inflammatory potential of GCs has led to the application of 
exogenous GCs for the treatment of a variety of inflammatory 
disorders such as asthma, rheumatoid arthritis, and inflamma-
tory bowel diseases (53, 54). GCs are also prescribed to trans-
plantation patients to prevent organ rejection and used for the 
treatment of lymphoid cancers including leukemia, lymphoma, 
and myeloma (44, 51, 55).
Due to their pleiotropic actions, the use of exogenous GCs 
has two major drawbacks. First, high therapeutic doses used 
to reach desired physiological effects also induce undesired 
side-effects including osteoporosis, diabetes, and hypertension 
(48, 54, 56). Second, prolonged and/or highly dosed GC use can 
lead to GC resistance. This phenomenon has been discussed 
extensively (48, 57, 58).
3.2. GR Structure and isoforms
GCs exert their effects mainly by binding to the cytosolic glu-
cocorticoid receptor (GR), a member of the nuclear receptor 
superfamily that is ubiquitously expressed (46, 51, 59). The 
human GR-coding nr3c1 gene is located on chromosome 5. 
Transcription generates multiple GR isoforms due to alterna-
tive splicing (45, 48). Each isoform is composed of three major 
functional domains: an N-terminal domain (NTD), a central 
 DNA-binding domain (DBD), and a C-terminal ligand-binding 
domain (LBD) (Figure 1). The NTD mediates the recruitment of 
the basal transcriptional machinery and contains the transcrip-
tional activation function 1 (AF-1) domain with residues that 
undergo posttranslational modifications (PTMs) and interact 
with cofactors in a ligand-independent way (45, 47). The DBD 
contains two zinc fingers that regulate GR dimerization and 
DNA binding (45, 56). The DBD is linked to the LBD via a hinge 
region. The LBD forms a hydrophobic ligand-binding pocket and 
contains the second transcriptional activation function domain 
(AF-2), which is responsible for ligand-dependent interaction 
with coregulators and recruitment of the basal transcriptional 
machinery (45–47). The receptor also contains two nuclear 
localization signals (NLS1 and NLS2, Figure 1) at the junction of 
the DBD and the hinge region, and within the LBD (45).
Alternative splicing of the LBD of the human GR gene gener-
ates GRα and GRβ—the best characterized isoforms of GR (45). 
GRα is the classic GR protein that mediates the majority of GCs 
actions. GRβ is considered a dominant inhibitor of GRα that 
resides constitutively in the nucleus but cannot bind to GCs and 
has no direct effect on GC-responsive genes. However, GRβ can 
antagonize the activity of GRα by competing for glucocorticoid 
response element (GRE) binding or for cofactors, or by formation 
of inactive GRα/GRβ heterodimers (45, 48). In general, the expres-
sion of GRβ is low but can be enhanced by pro-inflammatory 
cytokines (e.g., TNF and IL-1) and other immune activators (e.g., 
microbial superantigens) (60, 61). Increased GRβ expression has 
been involved in GC resistance in a variety of inflammatory 
diseases (45, 50). GRγ, GR-A, and GR-P are the three other tran-
scriptional GR isoforms. They are less characterized than GRα 
and GRβ, but GRγ and GR-P are also known to be involved in 
GC resistance (62–64).
Alternative translation initiation results in further division of 
each isoform into subtypes. For instance, GRα has 8 subtypes, 
which are the result of 8 highly conserved start codons present 
in the GR mRNA. GRα-A is the full-length receptor and is the 
most abundant GR protein in many cell types, together with 
GRα-B (45). GR is also subject to various posttranslational 
modifications including phosphorylation, SUMOylation, and 
ubiquitination (43, 48, 65). Unless specified otherwise, it is always 
GRα that is referred to, since most known GC-mediated actions 
are exerted via this receptor isoform.
3.3. Molecular Mechanisms of GC Action
In the absence of ligand, GR mainly resides in the cytoplasm 
in association with chaperone proteins (e.g., hsp90, hsp70, and 
hsp90-binding protein p23) and immunophilins [e.g., FK506-
binding protein (FKBP)-51 and FKBP-52] (45). Upon ligand 
binding, GR undergoes a conformational change that induces 
partial dissociation of the chaperone complex and exposes the 
nuclear localization sequences (43, 45). FKBP-51 is substituted 
by FKBP-52, and the transport protein dynein transports 
the GR complex along the cytoskeletal tracts to the nucleus 
(44, 65). This process also depends on importin-α and importin 
13 (56, 57). In the nucleus, the complex dissociates and GR binds 
to DNA in homodimeric form (44). The cellular localization of 
GR is a dynamic process, since both active and inactive forms of 
the receptor have been demonstrated to shuttle back and forth 
between nucleus and cytoplasm (49, 65). Nevertheless, in most 
cases GR resides in the cytosol in the absence of GCs, while it 
translocates to the nucleus when bound to its ligand. The effect 
on transcription depends on binding to DNA and/or other tran-
scription factors and on the recruitment of GR coregulators. The 
latter proteins include coactivators and corepressors that assist in 
GR transcriptional activity (66).
Binding of homodimeric GR to glucocorticoid response 
elements (GREs) results in transcriptional activation and rapid 
switches between the bound and the unbound state of GR (45, 49). 
This interaction induces transcription of various genes including 
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FiGURe 1 | Splice variants and posttranslational modifications of the human glucocorticoid receptor (GR). (A) The splice variant GRβ differs from GRα in 
the C-terminal LBD, does not bind GCs, and acts as a dominant negative regulator of GRα. GRγ contains an insertion of an additional arginine residue in the DBD. 
This impairs its ability to regulate specific GC-responsive genes. GR-A and GR-P miss large regions in the LBD and fail to bind GCs, based on Oakley and Cidlowski 
(45). (B) GR contains several residues subjected to posttranslational modifications. AF, activation function; DBD, DNA-binding domain; HR, hinge region; LBD, 
ligand-binding domain; NLS, nuclear localization signal; NTD, N-terminal domain; P, phosphorylation; S, sumoylation; U, ubiquitination.
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sphingosine kinase 1 (Sphk1) and TGF-stimulated clone 22 
domain protein-3 (Tsc22d3), the coding gene for GC-induced 
leucine zipper (GILZ) (56, 67). The latter protein is reported 
to bind to NF-κB and AP-1, and the protective effect of this 
interaction has been shown in several inflammatory models (56). 
The promotor region of MAPK phosphatase-1 gene mkp1 also 
contains a GRE site (56). The corresponding protein, MKP-1 or 
dual specificity phosphatase-1 (DUSP1) is a MAPK phosphatase 
that inactivates kinases involved in activation of AP-1—ERKs, 
p38, and JNK. MAPKs are also involved in the fine-tuning of 
NF-κB signaling (56, 68). Other anti-inflammatory mediators 
induced by GR bound to GREs include IL-10 and annexin-1 
(AnxA1) (56, 69).
Moreover, GC-bound GR can also inhibit gene transcrip-
tion via negative GREs (nGREs) with consensus sequence 
CTCC(n)0−2GGAGA. The nature of this sequence does not allow 
GR dimerization, thus these inhibitory actions are mediated 
by monomeric GR (70). GR via an nGRE reduces expression 
of thymic stromal lymphopoietin (TSLP). The GR-dependent 
repression through nGRE is probably mediated via the assembly 
of a corepressor complex and the recruitment of histone deacety-
lases (70).
DNA-bound GR can still interact with other transcription 
factors via a mechanism called composite regulation. GR and its 
interacting transcription factors both bind to their own response 
element and influence each others’ transcription in a DNA-
dependent manner (65, 68). In the hypothalamus, GR bound 
to an nGRE interacts with DNA-bound AP-1 and negatively 
regulates CRH (71).
GR can also bind to DNA-bound transcription factors, with-
out interacting with DNA itself (65, 72). This process—called 
tethering—occurs at lower cortisol levels than GRE-mediated 
GR actions (48). However, it remains unclear if GR tethers 
in a monomeric or dimeric form or works in yet another 
fashion (73, 74). Nuclear factor kappa B (NF-κB) and activa-
tor protein 1 (AP-1) belong to the best characterized proteins 
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that are tethered by GR (44). The GR-mediated inhibition of 
NF-κB and AP-1 represents the main mechanism for the anti-
inflammatory actions of GCs, but GR can also interact with 
other transcription factors including interferon regulatory 
factor 3 (IRF3), signal transducer and activator of transcrip-
tion (STAT) 3 and 5, and GATA3 (43, 65, 68, 75). GR-mediated 
tethering onto NF-κB and AP-1 implies direct binding of 
presumably monomeric GR to the DNA-bound Jun- and the 
p65-subunit (45, 65, 68, 76); however, the surface part of GR 
involved in these interactions differs for AP-1 and NF-κB 
(48). Tethering between GR and these transcription factors 
is reciprocal, which implies that AP-1 and NF-κB can inhibit 
DNA-bound GR (47, 51, 68). GR can also inhibit AP-1 and 
NF-κB through other mechanisms including the cofactor 
GRIP1-mediated inhibition of NF-κB/IRF3 dimer formation, 
via reduced histone acetyltransferase (HAT) activity of CBP 
or via recruitment of histone deacetylase 2 (HDAC2). The 
latter mechanism seems to be responsible for GR-mediated 
inhibition of CXCL8 (IL-8) expression (55, 65, 68). GCs also 
repress NF-κB-driven genes via upregulation of the cytoplas-
mic NF-κB inhibitor (IκB-α) (44).
Additionally, GR exerts some of its actions in a rapid non-
genomic mode within minutes. Thereby GR influences signaling 
pathways, possibly via membrane-associated GR and a second 
messenger cascade (48, 51, 55, 77). Only recently it has been 
appreciated that GR elicits also pro-inflammatory pathways 
to prime cells for an adequate subsequent anti-inflammatory 
response (55).
4. ReGULATiON OF eNDOTHeLiAL 
PHYSiOLOGY BY GCs
GCs exert various effects on immune cell function. GCs 
cause immunosuppression in pro-inflammatory T cells while 
increasing the activity of regulatory T cells. GCs seem to affect 
B cell proliferation. In macrophages, the effects of GCs are 
concentration-dependent and range from immunosuppression 
to immunostimulation. Furthermore, GCs mediate the induc-
tion of a tolerogenic phenotype in dendritic cells (2). GCs also 
induce apoptosis in various types of immune cells including T 
cells, B cells, and plasmacytoid dendritic cells (78–80). This 
process plays an important role in the development of the 
immune system and in fine-tuning of its function. Interestingly, 
GCs have opposite effects in macrophages and mediate their 
survival (81). GC-induced apoptosis also has been extensively 
reviewed in other cell types; however, the effects of GCs on 
endothelial apoptosis remain insufficiently studied (82).
It becomes more and more clear that GCs also regulate mul-
tiple aspects of endothelial physiology (Figure  2). GCs inhibit 
pro-inflammatory signaling pathways in endothelium and 
induce protective molecules that maintain endothelial function, 
especially upon inflammation. For instance, dexamethasone 
blocks nuclear translocation of NF-κB and reduces the binding 
of AP-1 and GATA to DNA in endothelial cells (83). GCs induce 
MKP-1 (also known as DUSP1), which inhibits MAPK signaling 
pathways, and tristetraprolin (TTP, also known as ZFP36), which 
destabilizes mRNAs of pro-inflammatory cytokines (84, 85). 
AnxA1, induced by GCs in endothelium, causes leukocyte detach-
ment and regulates BBB integrity (86–88). Moreover, AnxA1 
inhibits phospholipase A2, an enzyme that releases arachidonic 
acid from phospholipids to produce pro-inflammatory mediators 
such as prostaglandins and leukotrienes via cyclooxygenase (89).
GCs inhibit the endothelial production of several pro-inflam-
matory cytokines and chemokines including IL-6, IL-17F, CXCL8 
(IL-8), and CCL2 (MCP-1) (84, 85, 90). GCs also downregulate 
ICAM-1, VCAM-1, and E-selectin (91–93). Moreover, GCs reduce 
levels of soluble forms of ICAM-1, VCAM-1, and E-selectin 
(sICAM-1, sVCAM-1, and sE-selectin) (94). Interestingly, GCs 
may also downregulate HLA-DR in IFN-γ-stimulated endothelial 
cells (92). Overall, GCs decrease leukocyte transmigration across 
the endothelium, thus limiting inflammation (95).
GCs also increase the activity of eNOS—a critical mediator 
of vascular integrity (96). Release of NO in the lumen inhibits 
platelet aggregation and leukocyte adhesion (97). Conversely, 
Iuchi et al. showed that GC excess induces reactive oxygen species 
and peroxynitrite formation, with possible detrimental effects on 
the vasculature (98).
Disruption of the endothelial barrier integrity is a common 
feature of various diseases including multiple sclerosis (MS) 
and stroke and leads to edema (99). GCs preserve endothelial 
barrier integrity through upregulation of junctional proteins 
such as occludin, claudin-5, and VE-cadherin (100–102) and 
down-regulation of MMP-9—an enzyme involved in junctional 
protein cleavage (103–105). GCs also induce endogenous MMP-9 
inhibitors—TIMP-3 and TIMP-1 (103, 106). However, the induc-
tion of TIMP-1 seems controversial since contradictory results 
exist (106). Since MMP-9 is able to cleave CXCL8 (IL-8) and dras-
tically potentiates its activities (107), it is tempting to speculate 
that downregulation of MMP-9 by GCs further affects neutrophil 
chemoattraction at the endothelial surface.
In summary, GCs influence endothelial barrier integrity, 
inhibit pro-inflammatory transcription factors, and induce 
protective molecules in endothelium (Figure 2). Investigation of 
molecular mechanisms of GC action in endothelium will enable 
comparison of these to the extensive data on regulation of inflam-
mation by GC in other cell types.
5. ReGULATiON OF eNDOTHeLiAL  
GC SeNSiTiviTY
Although GCs have been the mainstay therapy for inflamma-
tory diseases since 1950, GC treatment possesses significant 
challenges such as reduced efficacy and/or development of GC 
resistance (108). GC resistance has been reported in various dis-
eases such as asthma and chronic obstructive pulmonary disease 
(COPD) (109) and in different cells types including peripheral 
blood mononuclear cells (PBMCs), B cells, and alveolar mac-
rophages. A wide range of mechanisms causing GC resistance 
in these cell types have been described including increased GRβ 
expression, posttranslational GR modification, impaired nuclear 
translocation of GR, reduced MKP-1 expression, and decreased 
activity of HDAC2 (58, 110–113).
A limited number of studies addressed GC sensitiv-
ity of endothelium uncovering several mechanisms that 
FiGURe 2 | GCs exert specific actions in endothelial cells. In general, GCs have a variety of cell type-specific effects. This figure depicts GC actions that  
have been described in endothelium. After entering an endothelial cell, GCs bind to GC receptor (GR) and translocate to the nucleus. GR bound to GCs inhibits 
pro-inflammatory pathways by limiting GATA and AP-1 DNA binding and NF-κB translocation. GCs decrease levels of adhesion molecules (VCAM-1, ICAM-1, and 
E-selectin) and also their soluble forms and MMP-9 while increasing levels of junctional proteins—occludin, claudin-5, and VE-cadherin. GCs induce protective 
molecules such as AnxA1, TTP, MKP-1, and TIMPs. Furthermore, GCs reduce levels of IL-6, IL-17F, CXCL8 (IL-8), and CCL2 (MCP-1). Stimulation with GCs 
increases the activity of eNOS—a critical mediator of vascular integrity. Induction of ROS represents detrimental effects of GC excess on the vasculature.
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regulate the response of endothelium to GCs (Figure  3). 
In dexamethasone-resistant HUVECs, GR interacted more 
strongly with BCL2-associated athanogene 1 (BAG1) protein 
than in dexamethasone-sensitive HUVECs (114). In general, 
BAG1 is a cytoplasmic protein, which can translocate to the 
nucleus and bind to DNA, decreasing GR transactivation (115). 
BAG1 also interferes with GR folding through interaction with 
HSP70 (116). Moreover, BAG1 may target interacting proteins 
for proteasomal degradation (117). In HUVECs, proteasome 
inhibition increased GR protein levels and abolished differences 
between GC-sensitive and GC-resistant cells, suggesting that 
 BAG1-mediated proteasomal degradation of GR accounts in 
part for the human variability in endothelial sensitivity to GCs 
(114). In vivo, proteasome inhibition improved GC sensitivity of 
endothelium and protected against brain edema (118).
Epigenetic mechanisms such as DNA methylation and 
histone modifications also regulate GC sensitivity of endothe-
lial cells. Dexamethasone-sensitive and dexamethasone-
resistant HUVECs have different GR promoter methylation 
patterns (119). The GR gene contains several variants of the 
untranslated exon 1:1A–1I (120). Each of these variants has 
its own promoter. Dexamethasone-sensitive cells show higher 
methylation levels of promoter 1D and lower methylation 
levels of promoter 1F. Pharmacological demethylation with 
5-aza-2-deoxycytidine increased the mRNA expression of all 
isoforms (except 1D in resistant HUVECs) and enhanced the GC 
sensitivity (119). Another epigenetic mechanism that influences 
endothelial GC sensitivity involves Sin3A–HDAC. This multi-
protein complex that regulates gene expression via histone dea-
cetylation consists of SAP30, Sin3, histone deacetylases HDAC1 
and HDAC2, histone-binding proteins RbAp46 and RbAp48, 
and other proteins. SAP30 represses gene transcription via 
tethering to gene promoters (121). Poor expression of Sap30 has 
been suggested as an explanation of impaired transrepression in 
HUVECs (122). Transgenic overexpression of SAP30 in HUVECs 
and analysis of its expression under inflammatory conditions 
would also improve the current understanding of how GC sensi-
tivity is regulated in endothelium.
Variations in the expression of the GC-activating and -deac-
tivating enzymes 11β-HSD1 and 11β-HSD2 have been described 
in endothelial cells (123). However, it remains unclear to what 
extent this affects the GC sensitivity.
In conclusion, the currently known mechanisms regulating 
GC sensitivity in endothelial cells summarized in Figure 3 include 
proteasomal degradation of GR and epigenetic modifications. 
However, the mechanisms that control GC sensitivity are com-
plex and often cell type specific. The regulation of GC sensitivity 
in endothelial cells has not yet been sufficiently addressed, in par-
ticular under inflammatory conditions. Since endothelium plays 
a crucial role in inflammation, we believe that further studies on 
this subject will open up new perspectives for the development 
and improvement of the current treatment strategies.
FiGURe 3 | Proteasomal degradation and epigenetic modifications 
regulate glucocorticoid sensitivity in endothelial cells. Proteasomal 
degradation of the glucocorticoid receptor (GR) impairs GR activity and 
prevents physiological actions of GCs. In dexamethasone-resistant HUVECs, 
GR associates with the proteasomal recruiting protein BCL2-associated 
athanogene 1 (BAG1). This results in a shorter half-life of GR. In HUVECs,  
low induction of SAP30 (component of Sin3A-histone deacetylase complex) 
impairs GR-mediated transrepression and leads to lower GC sensitivity. 
Furthermore, higher methylation of the promoters of the different variants  
of the untranslated exon 1 of GR leads to lower expression and therefore 
decreased GC sensitivity.
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6. eNDOTHeLiAL ReSPONSe TO GCs iN 
MULTiPLe SCLeROSiS
6.1. BBB integrity in Multiple Sclerosis
Multiple sclerosis (MS) is mediated by autoreactive T cells that 
attack the myelin-sheath, but other inflammatory cells such as 
B cells, macrophages, and microglia may be as well involved in 
the pathogenesis. T cells infiltrate into the central nervous system 
(CNS) causing massive inflammation (124, 125). MS affects TJs 
and AJs protein expression in patients. Incubation of SVEC4–10 
endothelial cells with serum from patients with MS in exacerba-
tion phase reduced the levels of occludin and VE-cadherin (126). 
Claudin-5 expression was downregulated in immortalized human 
brain microvascular endothelial cells (TY09) after treatment with 
sera from the relapse phase of relapse-remitting MS (RRMS-R) 
or secondary progressive MS (SPMS) (127). Cytokines (TNF 
or IL-6) also reduced expression of TJ proteins in human brain 
microvascular endothelial cells (128).
6.2. effects of GCs on BBB in Multiple 
Sclerosis
Episodes of neurological deficit (relapses) and periods of recovery 
(remission) characterize the most common form of MS. GCs 
remain standard therapy for MS (129). High-dose short-term 
GCs are prescribed to manage relapses although the opinions 
of neurologists and national guidelines on dose and duration 
of GC treatment vary (130, 131). In brain endothelial cells, GCs 
upregulate AnxA1 that regulates endothelial barrier integrity 
(86, 88). Indeed, AnxA1 KO mice show disrupted BBB as a result 
of actin cytoskeleton rearrangements (88). Junctional proteins 
also belong to GC target genes (132, 133). GCs induce occludin, 
claudin-5, and VE-cadherin in brain microvascular endothelial 
cells preventing endothelial barrier damage (100, 102). However, 
sera from patients with MS (with active disease and remission) 
downregulated expression of claudin-5 and occludin in cEND 
cells. Furthermore, dexamethasone failed to restore expression 
of these proteins (104). This suggests that treatment of cEND 
cells with sera from patients with MS impairs transactivation of 
junctional protein genes by GCs.
GCs downregulate expression of matrix metalloproteinase-9 
(MMP-9, a key mediator of extracellular matrix remodeling and 
BBB disruption) in mouse brain endothelial cells incubated with 
sera from patients with MS (103, 104). Similarly, treatment with 
dexamethasone inhibits MMP-9 expression in primary rat brain 
endothelial cells stimulated with TNF or IL-1β (134). GCs also 
induce expression of the tissue inhibitor of metalloproteinases-1 
(TIMP-1) (103).
High-dose methylprednisolone reduced expression of adhe-
sion molecules (ICAM-1, VCAM-1) in human brain microvas-
cular endothelial cells stimulated with TNF and in endothelial 
cells from patients with MS (91, 92). Methylprednisolone limited 
migration of PBMCs through endothelial barrier after 3 h, but 
this effect was less pronounced after 24 h (95). GCs also limit 
interactions of leukocytes with endothelium through down-
regulation of integrins (VLA-4, LFA-1) (135) and induction of 
AnxA1 that causes detachment of leukocytes from endothelial 
cells (87, 136).
Overall, in vitro studies indicate that GCs restore BBB integrity 
through induction of TJ proteins and protective molecules such 
as TIMPs. Inhibition of damaging molecules (MMP-9) and 
leukocyte transmigration constitute another important mode of 
GC action in MS.
7. eNDOTHeLiAL ReSPONSe TO GCs iN 
STROKe
7.1. BBB integrity in ischemic Stroke
Ischemic stroke consists of two phases with pathological impact: 
ischemia and reperfusion. This induces oxidative stress in the 
brain and results in TJs damage and BBB disruption (15, 137). 
During the ischemic phase, loss of regional cerebral blood 
flow leads to deprivation of oxygen and nutrients in the sur-
rounding tissue. Reperfusion reestablishes cerebral blood flow 
to the ischemic brain, but it also causes additional damage due 
to oxidative stress leading to increased blood–brain barrier 
permeability (15).
Oxygen and glucose deprivation and subsequent reperfusion 
disrupt TJs. In vitro experiments showed that hypoxia reduces clau-
din-5 levels and changes its localization in the plasma membrane 
FiGURe 4 | endothelial GR signaling is beneficial in animal models of sepsis and atherosclerosis but harmful in stroke model. Mice with conditional GR 
deletion in endothelium provide a useful tool to study the role of endothelial GR signaling. In a model of stroke with these mice, it was shown that endothelial GR 
signaling increases infarct volume and reduces levels of junctional proteins (TJs) leading to increase in BBB permeability. In septic mice, the endothelial GR protects 
against LPS-induced inflammation and mortality. In an in vivo model of atherosclerosis, the endothelial GR reduces lesions and macrophage recruitment.
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in bEND.3 cells (138). MMP-2 and caveolin-1 (induced upon 
hypoxia) mediate occludin degradation and claudin-5 redistri-
bution (139). Caspase-3, expressed by rat brain endothelial cells 
stimulated with TNF, is another enzyme involved in TJ disruption 
during ischemia (140, 141). Moreover, other molecules secreted 
in the brain such as VEGF and thrombin increase BBB perme-
ability during stroke (142, 143).
7.2. effects of GCs on BBB in ischemic 
Stroke
Benefits from steroid use in stroke remain controversial according 
to clinical trials (144, 145). In vivo and in vitro experiments pro-
vide even more contradictory data. In one study, high-dose GCs 
administered within 2 h of transient cerebral ischemia, increase 
endothelial NOS activity and reduce infarct size. The underlying 
mechanism for activation of endothelial NOS by GCs involves the 
PI3K/Akt kinases (96). However, other studies reported lack of 
effect (145, 146) or even damaging effects (147) of GCs in stroke. 
GC signaling in myeloid and endothelial cells may aggravate 
ischemic infarcts (Figure  4) (147). Endothelial GR signaling 
reduces levels of junctional proteins in stroke since Tie-2-GR 
KO mice (with endothelium-specific GR deletion) produce more 
claudin-5, occluding, and caveolin-1 than WT mice after middle 
cerebral brain occlusion. This suggests that endogenous GCs, 
released post-injury, signal through endothelial GR and reduce 
levels of junctional proteins. Moreover, deletion of endothelial 
GR reduces infarct volume (147). These data are in contrast with 
the classic notion that synthetic GCs induce junctional proteins 
[see section 4 and Ref. (132)]. Thus, the classic inductive effects 
of GC on TJ proteins are overshadowed and even inverted during 
ischemic stroke. The reasons for this discrepancy remain unclear. 
GR deletion abolishes the physiological effects of endogenous and 
exogenous GCs and could possibly also affect GC-independent 
processes. Therefore, the consequences of GR deletion may not 
be in line with described effects of high doses of exogenous GCs.
Kleinschnitz and colleagues showed occurrence of GC resist-
ance at the hypoxic blood–brain barrier (118). Dexamethasone 
failed to induce junctional proteins in murine brain microvascu-
lar endothelial cells (cEND) following oxygen and glucose dep-
rivation. Proteasome-dependent degradation of GR diminished 
transactivation of GC target genes. Bortezomib—a proteasome 
inhibitor—restored induction of junctional proteins by GCs after 
oxygen and glucose deprivation. Consequently, mice treated with 
bortezomib and GCs developed less edema (118).
In conclusion, the effects of GCs in stroke remain insufficiently 
understood. Beneficial, damaging effects and even GC resistance 
have been suggested.
8. eNDOTHeLiAL ReSPONSe TO GCs iN 
SePSiS
8.1. Activation of endothelium in Sepsis
Sepsis—a life-threatening organ dysfunction caused by a dys-
regulated host response to infection (148)—constitutes the most 
common cause of death in non-coronary intensive care units. 
The pathophysiology of sepsis remains poorly understood, and 
the host response mainly determines patient outcome. Alteration 
of endothelial cell function plays a crucial role in the patho-
physiology of sepsis (149). Endothelial cells undergo excessive 
activation that involves release of pro-inflammatory mediators 
to recruit leukocytes and promote clotting to immobilize the 
pathogens upon tissue invasion. Functional changes observed 
after activation of endothelium include increased cell adhesion 
and leukocyte trafficking, loss of barrier function, and programed 
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cell death (149). Cytokines such as VEGF-A, colony-stimulating 
factor 1 (CSF1), IL-1β, and TNF secreted by macrophages dur-
ing tissue injury bind to receptors on endothelium resulting in 
endothelial activation and expression of adhesion molecules such 
as P-selectin, E-selectin, ICAM-1, and VCAM-1 (150, 151).
The NF-κB pathway plays a central role in the induction 
of cytokines and adhesion molecules mentioned above (152) 
and mediates multiple organ inflammation in sepsis (153). 
Endothelial ROS-mediated NF-κB and AP-1 activation as well 
as leukocyte recruitment in the lungs of septic mice require 
active MAPK kinase kinase 3 (154). Double transgenic mice that 
overexpress a degradation-resistant form of the NF-κB inhibi-
tor IκBα in vascular endothelium showed endothelial selective 
NF-κB blockade, inhibition of adhesion molecules, reduced 
neutrophil infiltration into different organs, and decreased 
endothelial permeability after LPS challenge (153). In support, 
another study showed that inhibition of NF-κB may be beneficial 
to the microvasculature during endotoxemia. TNF treatment 
of mouse microvascular endothelial cells induced cytotoxicity 
and production of pro-inflammatory cytokines including IL-1β, 
IL-6, CCL5 (RANTES), and iNOS expression. NF-κB inhibition 
abrogated these changes (155).
Endothelial cells together with leukocytes recognize patho-
gens via pattern recognition receptors that interact with micro-
bial products (156, 157). Bacterial products such as LPS from 
 Gram-negative bacteria interact with toll-like receptors (TLRs) 
leading to the activation of inflammatory and coagulation path-
ways (158). In endothelial cells, TLR4 may be localized intracellu-
larly and requires then LPS internalization for its activation. The 
uptake system also depends on LPS binding protein and soluble 
CD14 (159). LPS induces CCL2 (MCP-1) secretion in activated 
human endothelial cells (HUVECs) through non-receptor 
tyrosine kinase 2 (Pyk2) activation and p38 MAPK phospho-
rylation (160). LPS and non-LPS components of meningococci 
(human pathogens that cause fatal sepsis and meningitis) can 
upregulate E-selectin expression in human primary endothelial 
cells (HUVECs) leading to neutrophil recruitment. The LPS-
independent mechanism involves activation of the activating 
transcription factor 2 (ATF2) via p38 MAPK (161).
Caveolin-1 (a signaling protein associated with caveolae—
small invaginations of the plasma membrane in endothelial cells) 
regulates the inflammatory response to LPS mediated by TLR4. 
After LPS exposure, caveolin-1 undergoes phosphorylation 
and interacts with TLR4 resulting in NF-κB activation and pro-
inflammatory cytokine expression in mouse lung microvascular 
endothelial cells. Mutation of the phosphorylation site in caveo-
lin-1 protected mice from septic shock after LPS challenge (162). 
P120-catenin (p120)—a protein expressed in adherent cells—also 
regulates TLR4 signaling after LPS challenge. P120 blocks inter-
action of TLR4 with the adaptor molecule MyD88 thus inhibiting 
TLR4 signaling and NF-κB activation in endothelial cells. In mice 
injected with LPS, p120 levels were inversely correlated with 
inflammation severity. P120 suppression in lung endothelial cells 
in mice with siRNA resulted in greater susceptibility to LPS and 
higher mortality. P120 blockade also increased ICAM-1, TNF, 
and IL-6 expression after LPS stimulation (163).
8.2. endothelial Barrier Breakdown in 
Sepsis
Hyperpermeability of endothelium is a hallmark of sepsis and 
causes tissue edema (149, 164). ANG1 and ANG2—important 
biomarkers of endothelial dysfunction—bind to Tie-2 receptor on 
endothelial cells. Under physiological conditions, ANG1 levels are 
higher and trigger pro-survival and anti-inflammatory pathways 
in endothelium. In sepsis, ANG2 is released from Weibel–Palade 
bodies. ANG2 Tie-2 interaction activates pro-inflammatory, 
pro-thrombic pathways and vascular leakage (150, 151). Septic 
patients show elevated serum levels of ANG2. Incubation of 
human microvascular endothelial cells with serum from septic 
patients disrupted endothelial barrier integrity. Moreover, ANG2 
alone can induce such effects and excessive systemic ANG2 
levels cause pulmonary leakage in healthy mice (165). Activated 
protein C (APC) upregulates Tie-2 and ANG1 expression 
and enhances endothelial barrier function. APC treatment 
of HUVECs reduces permeability and upregulates the tight 
junction-associated protein zona occludens (ZO-1) (166).
MMPs modulate endothelial barrier integrity through pro-
cessing of adherens and tight junction proteins (167). MMP-8 
inhibition protects mice from death in sepsis (168–170). Arpino 
and colleagues showed that inhibition of metalloproteinase-
mediated adherens junctions’ disruption by tissue inhibitor of 
metalloproteinases-3 (TIMP-3) preserves normal endothelial 
barrier integrity. Pulmonary microvascular endothelial cells 
monolayers from TIMP-3 KO mice spontaneously displayed bar-
rier dysfunction associated with disrupted surface VE-cadherin 
localization (167).
Bacterial products and host inflammatory mediators are also 
involved in increased endothelial permeability during sepsis. 
The neisserial antigen fragment C2 released after proteolysis of 
the surface-exposed protein neisserial heparin binding antigen 
(NHBA) from Neisseria meningitidis increases endothelial 
barrier permeability via internalization of VE-cadherin. ROS 
induction by C2 results in VE-cadherin phosphorylation and 
internalization contributing to severe vascular leakage observed 
in meningococcal sepsis (171). TNF or LPS treatment of human 
dermal microvascular endothelial cells also results in endothelial 
barrier disruption. Soluble VE-cadherin, released by a disintegrin 
and metalloproteinase 10 (ADAM10) in the culture supernatant, 
inhibits VE-cadherin binding thus contributing to breakdown of 
endothelial barrier during inflammation. Inhibition of ADAM10 
blocks soluble VE-cadherin production and preserves endothe-
lial barrier integrity upon TNF or LPS stimulation. In septic 
patients, plasma levels of soluble VE-cadherin correlate with 
disease  severity (172).
Stimulation of human brain microvascular endothelial cells 
with LPS also reduces occludin and claudin-5 levels resulting in 
endothelial barrier breakdown. This is mediated by LPS-induced 
ROS. Indeed, adenoviral expression of superoxide dismutase 
or inhibition of NADPH oxidase by AMP-activated protein 
kinase (AMPK)—an enzyme that regulates redox homeostasis 
in endothelial cells—abolished these effects (173). Kang and col-
leagues showed that heat shock protein A12B (HSPA12B) also 
rescues endothelial barrier integrity upon LPS stimulation in 
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HUVECs. HSPA12B induces VE-cadherin, myosin light chain, 
and CDC42. Moreover, HSPA12B silencing increased lung per-
meability in septic mice (174).
8.3. GC Therapy in Sepsis
Despite over 30 years of investigation, the use of GCs in septic 
patients remains controversial (175, 176). Prednisolone was ben-
eficial in a model of Gram-negative sepsis in healthy volunteers. 
Treatment with prednisolone decreased plasma levels of TNF, 
IL-6, CXCL8 (IL-8), and CCL2 (MCP-1) and increased IL-10 
levels. Prednisolone also blocked neutrophil activation (177). 
However, short treatment with high-dose GCs was ineffective in 
the majority of studies performed in sepsis. Long course treat-
ment with a low dose seems a more promising strategy (178–180). 
The effects of GCs on coagulation, which is also involved in sepsis, 
constitute another controversial issue. GCs failed to attenuate the 
LPS-induced coagulation cascade in a human model of sepsis 
(177). In contrast, Bartko and coauthors showed that GCs locally 
reduce coagulation in a human model of lung inflammation with 
LPS (181). Different experimental settings used in these studies 
may in part explain contradictory results. Moreover, dexametha-
sone has been shown to enhance the stability of TF transcript 
in human monocytic cells stimulated with LPS (182), whereas 
in HUVECs, GR knockdown increased TF expression upon LPS 
stimulation (183). According to a systematic review, GCs appear 
to upregulate the activity of coagulation factors in healthy peo-
ple, whereas during active inflammation GCs decrease levels of 
fibrinogen and von Willebrand factor and increase plasminogen 
activator inhibitor-1 (PAI-1) levels (184).
Contradictory effects of GCs in sepsis may be related to the 
promoter polymorphism of the NF-κB1 gene. Hydrocortisone 
failed to inhibit LPS-induced NF-κB translocation in monocytes 
from patients with a deletion in the promoter region of NF-κB1 
gene (delATTG). As such, hydrocortisone treatment was also 
associated with increased 30-day mortality in these patients 
(185). This suggests that stratification of patients may help to 
predict the efficacy of GC treatment. This is also supported by 
an in  vivo study with a sepsis model induced by cecal ligation 
and puncture. Stratification of mice according to the levels of 
circulating IL-6 not only predicted mortality but also efficacy of 
GC treatment, as only mice with high IL-6 responded to the GC 
treatment (186).
Nitric oxide (NO)-releasing derivatives of glucocorticoids 
show enhanced anti-inflammatory properties and may provide 
another pathway to improve GC therapy in sepsis (187). In par-
ticular, a NO-releasing derivative of dexamethasone, ND8008, 
was found to be more effective than dexamethasone in reducing 
the inflammatory response in LPS-stimulated mouse peritoneal 
macrophages and in an in  vivo model of methicillin-resistant 
Staphylococcus aureus (MRSA) blood infection (188).
8.4. GR in Sepsis
Patients with septic shock exhibit high variability in GC respon-
siveness, and this may partially explain controversial effects of GC 
therapy in sepsis. Increased sickness was associated with lower 
GC sensitivity. However, GRβ and 11βHSD1 did not influence 
GC sensitivity in patients with sepsis (189). GR expression and 
translocation gradually decrease in experimental sepsis. This 
may explain why early dexamethasone treatment of septic mice 
improved clinical outcome compared to late treatment (190). 
Another study showed that GCs may worsen clinical outcome in 
septic patients with high GRβ levels through induction of miR-
124 in T cells that downregulate GRα expression (191). However, 
other GC-regulated genes have been shown to have beneficial 
effects in sepsis. miR-511, induced by GCs via GR, confers 
protection in  vivo against TNF-induced inflammation (192). 
In activated human CD4+ T cells, GCs induce miR-98 that 
inhibits the expression of pro-inflammatory mediators (193). 
Furthermore, GCs downregulate miR-155 resulting in reduction 
of inflammation in macrophages stimulated with LPS (194). 
GILZ protects SPRET/Ei mice against LPS-induced lethal 
inflammation (195). Pro-inflammatory cytokines and GCs, via 
GR, induce sphingosine kinase 1 (Sphk1) in a model of acute 
lung injury (ALI)—a complication of sepsis. This results in 
increase of sphingosine 1-phosphate levels (S1P), which bind to 
its receptor on the endothelium and triggers endothelial barrier 
 enhancement (67). GR-mediated immunosuppression in mac-
rophages improves survival during sepsis. Treatment of mice with 
a point mutation in the GR DNA-binding domain that impairs 
formation of transactivating GR dimers (GRdim) and mice lacking 
GR in macrophages with recombinant IL-1 receptor antagonist 
improves their survival after LPS challenge confirming that regu-
lation of IL-1β in macrophages by GCs plays essential role in the 
control of sepsis (196). Conditional GR deletion in macrophages 
results in greater mortality and cytokine induction after LPS 
treatment (197).
8.5. endothelial GR in Sepsis
Signaling through endothelial GR plays a beneficial role in models 
of sepsis (Figure 4). Mice with an endothelium-specific deletion 
of GR show increased mortality, higher levels of TNF, IL-6, and 
nitric oxide in comparison with control mice after challenge with 
LPS (183). GR deletion in HUVECs treated with LPS increases 
NF-κB levels and IL-6 levels suggesting that endothelial GR plays 
a crucial role in the regulation of the NF-κB pathway and nitric 
oxide synthesis. Moreover, mice lacking endothelial GR pre-
treated with dexamethasone show increased NF-κB activity after 
LPS injection (198). A possible limitation of this study is that GR 
deletion is driven by the Tie-1 promoter, which may be not fully 
endothelium-specific, as hematopoietic stem cells also express 
Tie-1 (199). Although GR-mediated induction of IκBα plays the 
main role in GC-induced suppression of NF-κB in monocytes and 
lymphocytes, in endothelial cells physical interaction between 
GR and NF-κB seems more important (200). Brostjan and col-
leagues also found that dexamethasone inhibits NF-κB-mediated 
transcription of E-selectin in porcine endothelial cells stimulated 
with LPS or TNF (93). Prednisolone reduced levels of soluble 
E-selectin and VCAM-1, respectively, in a human endotoxemia 
model (94). Maximal inhibition was achieved at 30 mg. However, 
levels of soluble ICAM-1 were not affected by the treatment (94). 
Interestingly, GCs also decreased LPS-induced expression of 
IL-17F in vitro in rat pulmonary endothelial cells and in vivo in a 
model of LPS-induced ALI. This was paralleled by inhibition of 
the lung injury (90).
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In summary, endothelial GR signaling protects against 
 LPS-induced sepsis (Figure  4). GCs also inhibit endothelial 
activation in in vitro and in vivo models of sepsis.
9. eNDOTHeLiAL ReSPONSe TO GCs iN 
vASCULiTiS
9.1. Activation of endothelium during 
vasculitis
Vasculitis is a heterogeneous group of disorders characterized 
by self-sustaining inflammation of blood vessels. Small vessel 
vasculitis affects venules and capillaries and is a hallmark of 
immune-complex vasculitis or necrotizing vasculitis. Giant cell 
arteritis and Takayasu’s arteritis involve medium and large ves-
sels (201). Diverse triggers such as bacterial and viral infections 
can cause vasculitis, but it can also occur as a primary disease of 
unknown origin (202, 203).
Activation of endothelium and leukocyte infiltration are hall-
marks of vasculitis and are tightly interrelated. Anti-endothelial 
antibodies (AECA) constitute an important cause of endothelial 
activation. Stimulation of human kidney endothelial cells 
with AECA upregulated vascular adhesion protein-1 (VAP-1), 
CCL2 (MCP-1), MHC class I-related antigen A (MICA), and 
CXCL6 (GCP-2) expression. AECA also activated c-Jun, ATF2, 
and NF-κB (204). IgA anti-endothelial cell antibodies present 
in sera from children with active Henoch–Schönlein purpura 
induce ERK phosphorylation and CXCL8 (IL-8) expression in 
HUVECs (205).
Furthermore, several cytokines and enzymes in the plasma of 
vasculitis patients contribute to endothelial activation. Plasma 
from patients with Kawasaki disease [acute febrile childhood 
vasculitis characterized by the development of coronary artery 
abnormalities in 25–30% of untreated patients (206)] activates 
HUVECs and induces MMP-9 expression. This effect is coun-
teracted by IFN-γ (207). Another study showed that sera from 
patients with acute Kawasaki disease induce ICAM-1 expression 
in HUVECs (208).
TNF-like weak inducer of apoptosis (TWEAK) serum levels of 
patients with acute Henoch–Schönlein purpura (the most com-
mon systemic vasculitis in children) are increased and correlate 
with severity of the disease. TWEAK induces CCL5 (RANTES) 
and CXCL8 (IL-8) expression in a human dermal endothelial cell 
line (209). TWEAK also upregulates E-selectin and ICAM-1 as 
shown in  vitro and in an in  vivo model of cutaneous vasculits 
(210).
Proteinase 3 (PR3), which is mainly produced by neutrophils 
and is the main autoantigen in granulomatosis with polyangiitis, 
binds also to endothelium and induces CXCL8 (IL-8) and CCL2 
(MCP-1) that provide chemotactic signals for neutrophils and 
monocytes. PR3 also upregulates the expression of adhesion 
molecules such as ICAM-1 on endothelial cells (211, 212).
Among the signaling pathways induced in endothelial cells dur-
ing vasculitis, NF-κB and endoplasmic reticulum stress response 
protein X-box binding protein-1 (XBP-1) appear important. In 
a local Shwartzman reaction model of TNF-induced vasculitis, 
XBP-1 contributes to the vascular damage as shown in mice with 
an endothelium-specific XBP-1 deletion (213). This transcription 
factor can be induced by TNF and upregulates the p65-subunit 
of NF-κB, resulting in sustained NF-κB-mediated transcription 
of pro-inflammatory molecules. XBP-1 also regulates leukocyte 
adhesion to endothelium in  vitro and neutrophil infiltration 
in vivo (213).
9.2. endothelial injury in vasculitis
Endothelial injury in vasculitis involves detachment of whole 
endothelial cells and apoptosis. These processes play an important 
role in the pathogenesis of vasculitis. Regulation of the balance 
between endothelial injury and endothelial repair is poorly stud-
ied. In children with active vasculitis the levels of VEGF, ANG2, 
circulating endothelial cells (CECs), and endothelial progenitor 
cells (EPCs) increase (214). EPCs migrate from bone marrow to 
the lesions. Chronic inflammation during vasculitis may impair 
EPC function and reduce endothelial repair capacity (215).
In a mouse model of Kawasaki disease, activation of Nlrp3 
inflammasome results in endothelial injury (216). In small vessel 
vasculitis, neutrophil-derived myeloperoxidase contributes to 
endothelial injury. It causes loss of cell membrane integrity and 
morphological changes in endothelial cells (217). The transfer 
of myeloperoxidase from neutrophils to endothelial cells is cell 
contact dependent and is mediated by β2 integrin (218).
Bacterial products constitute another group of agents involved 
in endothelial injury during vasculitis. Haemophilus somnus 
infection often causes vasculitis and thrombosis in bovines (219). 
This pathogen and its lipooligosaccharide induce apoptosis in 
bovine pulmonary artery endothelial cells in vitro (220).
9.3. GC Therapy in vasculitis
GC therapy remains the golden standard in vasculitis (221, 222). 
GCs are used to induce remission and as maintenance therapy 
(223). Antineutrophil cytoplasmic antibody (ANCA)-associated 
vasculitis (AAV) is a group of unique diseases characterized by 
necrotizing inflammation of small blood vessels and presence of 
ANCA (224). GCs constitute the main therapy for AAV due to 
their rapid onset of action (225) and are an effective treatment for 
non-severe relapses in the majority of patients with AAV (226). 
However, there is no consensus among clinicians on induction 
doses and therapeutic schedules of GC therapy in AAV to induce 
and maintain remission (225). Patients with systemic necrotiz-
ing vasculitis who do not respond to a sole GC treatment are 
prescribed GC combined with cytotoxic agents (227).
In patients with giant cell arteritis, treatment with high-dose 
GCs reduced neutrophil adhesion to endothelium already after 
48 h. However, 6 months after the GC dose the suppressor phe-
notype of neutrophils was less pronounced (228). Another study 
showed that GCs inhibit IL-17 release, but IFN-γ levels remained 
unaffected (222). A plethora of cytokines was identified in vas-
culitic lesions in giant cell arteritis with two dominant clusters: 
IL-6/IL-17 and IL-12/IFN-α. The IL-6/IL-17 cluster, active in 
early and untreated disease, is highly sensitive to GCs. Despite 
this inhibition, inflammation persists in patients with elevated 
levels of IL-12 and IFN-γ that are resistant to GCs (229). High 
doses of GCs inhibited IL-2 and IFN-γ from T cells, but IFN-γ 
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mRNA levels were only slightly affected in severe combined 
immunodeficiency (SCID) mice engrafted with human temporal 
arteries. Moreover, activation of macrophages was only partially 
inhibited by GCs in this model, suggesting a strong GC-resistant 
component (230).
9.4. Suppression of endothelial Response 
by GCs in vasculitis
Endothelial activation clearly plays a prominent role in the 
vascular damage and overall pathophysiology of the various 
vasculitides. Although GCs have in general multiple beneficial 
effects on endothelial cells (see section 4), it remains unclear 
to what extent the therapeutic effects of GCs in vasculitis are 
mediated through the endothelium. For instance, one study 
indicated that GCs improve flow-mediated dilation, a marker of 
endothelial function in giant cell arteritis patients (231), but a 
later and larger study failed to obtain statistical significance of this 
parameter (232). In an in  vitro model of vasculitis with 
HUVECs cocultured with neutrophils and stimulated with 
TNF or IL-1β, GCs inhibited E-selectin expression, which is 
involved in the damaging hyperadhesiveness of neutrophils to 
endothelium (233). Another study showed that dexamethasone 
inhibits IL-6 production and E-selectin expression in human 
coronary arterial endothelial cells stimulated with TNF (234).
Overall, more in  vivo studies are needed to delineate the 
endothelial response and sensitivity to GCs in vasculitis. For 
instance, experiments with mice with endothelium-specific dele-
tion of the GR may yield interesting insights.
10. eNDOTHeLiAL ReSPONSe TO GCs iN 
ATHeROSCLeROSiS
10.1. Activation of endothelium during 
Atherosclerosis
Atherosclerosis affects large vessels and is the primary cause of 
heart disease and stroke. High-fat, high-cholesterol diet causes 
accumulation of lipoprotein particles and their aggregates in the 
intima at the lesion sites of predilection (235). Low density lipo-
proteins (LDL) passively diffuse through TJs and accumulate in 
the subendothelial matrix. Oxidized LDL stimulate the endothe-
lium to produce adhesion molecules and reduce NO production, 
which is a critical mediator of vasorelaxation (235).
In animal models, endothelial cells in the arteries express 
VCAM-1 in response to cholesterol accumulation in the 
intima resulting in monocyte recruitment (236). Monocytes 
subsequently transmigrate into the intima, where they take up 
lipoproteins forming foam cells (235). Smooth muscle cells also 
express VCAM-1 that promotes recruitment and retention of 
mononuclear cells in the intima (237). Several pro-inflammatory 
mediators produced by endothelial cells play an important role 
in recruitment of immune cells (236). CCL2 (MCP-1) promotes 
monocyte recruitment and is the dominant mediator of mac-
rophage accumulation in atherosclerotic lesions (238). CCR2 KO 
mice developed less atherosclerotic lesions (239). Macrophage 
migration inhibitory factor (MIF)—a key regulator in chronic 
and acute inflammation—also plays a role in the pathogenesis of 
atherosclerosis and is upregulated in monocytes and endothelial 
cells in human atherosclerotic lesions (240, 241). MIF blockade 
results in plaque regression and lower monocyte and T cell content 
in the lesions (242). Tissue factor (TF) triggers coagulation and its 
elevated levels are found in atherosclerotic plaques. IL-33 induces 
TF expression in HUVECs and coronary artery endothelial 
cells in a ST2 and NF-κB-dependent manner. In human carotid 
atherosclerotic plaques, TF levels positively correlate with IL-33 
expression (243). Vascular endothelial cells and macrophages 
produce also T cell attractants CXCL9 (Mig), CXCL10 (IP-10), 
and CXCL11 (I-TAC). These chemokines play an important role 
in the recruitment of T cells within the lesions, since activated T 
cells express the corresponding receptor CXCR3 (244).
Bacterial infection-mediated inflammation has been shown 
to facilitate development of atherosclerosis via the follow-
ing mechanism: flagellin (principal component of bacterial 
 flagellum) induces interaction between NADPH oxidase-4 
(Nox4) and TLR5 (245). Nox4 seems unusual because it releases 
H2O2 in contrast to other Nox family members that produce 
superoxide (246). Nox4 and TLR5 interaction results in H2O2 
generation and induction of CXCL8 (IL-8) and ICAM-1 in 
human aortic endothelial cells. Nox4 deficiency results in resist-
ance to flagellin-induced atherosclerosis in ApoE KO mice (245). 
Porphyromonas gingivalis, a bacterial species that causes perio-
dontitis, impairs tube formation and induces adhesion molecules 
(ICAM-1, VCAM-1) in human coronary artery endothelial cells 
through TLR4 signaling (247).
10.2. The Role of endogenous GCs in 
Atherosclerosis
The link between GCs and the cardiovascular system is com-
plex. Epidemiological models showed correlation between 
endogenous plasma corticosteroid levels and severity of cardio-
vascular disease (248). The function of endogenous GCs in the 
development of atherosclerosis remains unclear. Adrenalectomy 
stimulates atherosclerosis in LDL receptor KO mice (249), but not 
in ApoE KO mice (250). Fine-tuning of GCs signaling by 11β-
HSD1 (converts inactive GCs into active form) and 11β-HSD2 
(converts active GCs into inactive form) also plays a role in 
atherosclerosis. Inhibition of 11β-HSD1 in atherosclerosis-prone 
apoE KO mice directly attenuates atherosclerotic plaques and 
decreases pro-inflammatory gene expression in the vasculature 
(251). 11β-HSD1 KO mice on apoE KO background challenged 
with western diet showed smaller plaques and lower macrophage 
content. Foam cell formation was decreased as well as expression 
of several TLRs (252). 11β-HSD1 inhibition reduces T cell infil-
tration, CCL2 (MCP-1) and VCAM-1 levels in atherosclerotic 
plaques (253).
10.3. Synthetic GCs in Atherosclerosis
The therapeutic effects of GCs in atherosclerosis development 
remain unclear. Mice with human-like lipoprotein metabolism 
treated with corticosterone showed a decrease in the total athero-
sclerotic lesion area and in macrophage content in the plaques. 
However, the treatment negatively affected body fat metabolism: 
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it increased body weight, subcutaneous adipose tissue, and food 
intake (254). Therefore, a localized treatment would be benefi-
cial, since this could help to avoid the systemic side-effects. This 
remains challenging because of the difficulty in implanting drug-
eluting devices without subjecting vessels to mechanical damage. 
Kastrup and colleagues developed a drug-eluting bioadhesive gel 
that can be glued onto the inside surface of blood vessels (255). 
Atherosclerotic mice treated with this steroid-eluting adhesive 
gel show lower macrophage content, less plasma cytokines, and 
biomarkers of inflammation in the plaques.
Importantly, atherosclerosis may even occur as a side effect 
of GC therapy. For instance, in patients with rheumatoid 
arthritis GC therapy was associated with carotid plaque, arterial 
incompressibility, and dose-dependently also with all-cause and 
cardiovascular mortality (256, 257). As a possible explanation, 
GCs induce macrophage adipocyte fatty acid-binding protein 
(FABP4), a pro-atherogenic protein upregulated by long chain 
fatty acids and oxidized LDL. Pitavastatin is a HMG-CoA 
reductase inhibitor that lowers cholesterol levels and therefore 
also FABP4 levels. When combined with dexamethasone pitavas-
tatin enhances in a synergistic manner FABP4 expression (258). 
Furthermore, co-treatment of apoE KO mice (challenged with 
high-fat diet) with dexamethasone and pitavastatin exacerbates 
diet-induced atherosclerotic lesions (259).
Although synthetic GCs reduce inflammation in animal 
models of atherosclerosis, metabolic side-effects may occur 
and overshadow beneficial effects. Localized GC treatment may 
therefore prove more effective and deserve further investigation.
10.4. effects of GCs on endothelium in 
Atherosclerosis
Endothelial GR suppresses atherogenesis in animals and plays 
an important role in the atheroprotective actions of endogenous 
GCs (Figure 4). ApoE KO mice lacking endothelial GR subjected 
to a high-fat diet developed more severe atherosclerotic lesions 
and showed increased macrophage recruitment (260).
GCs exert various anti-inflammatory actions such as inhibition 
of VCAM-1 and CCL2 (MCP-1) (see section 4) via endothelial 
GR. Two GC-inducible genes tristetraprolin (TTP, also known as 
ZFP36) and glucocorticoid-induced leucine zipper (GILZ, also 
known as TSC22 domain family protein-3) influence endothelial 
cell function during atherosclerosis (261, 262). GILZ is a key 
endogenous regulator of the immune response that interacts with 
signal transduction pathways (1). Degenerated aortocoronary 
saphenous vein bypass grafts (with inflammatory cell activation) 
showed lower protein and mRNA levels of GILZ in comparison 
with healthy controls. GILZ was also downregulated in HUVECs 
and macrophages upon TNF stimulation, and GILZ KO enhanced 
pro-inflammatory gene expression (261). TTP destabilizes 
pro-inflammatory cytokine mRNA through binding to AU-rich 
elements within their 3′-untranslated regions (263). LPS, GCs, 
and forskolin induce TTP expression in human aortic endothelial 
cells. Endothelial cells overlying atherosclerotic lesions in mice 
and humans express TTP that has been shown to reduce NF-κB 
activation during atherosclerosis (262).
In conclusion, the main protective effects of GCs on endothe-
lium during inflammation include inhibition of pro-inflammatory 
molecules (e.g., VCAM-1 and MCP-1) and induction of protec-
tive molecules (such as GILZ and TTP). Moreover, endothelial 
GR protects against atherosclerosis in in vivo models. However, 
the overall effects of GCs in atherosclerosis are complex and also 
include deleterious metabolic effects.
11. CONCLUSiON
A plethora of in  vivo and in  vitro studies have shown that the 
endothelium represents an important target for GCs. GCs 
induce junctional proteins and several protective molecules in 
endothelium. Furthermore, GCs inhibit endothelial expression 
of pro-inflammatory mediators such as cytokines, chemokines, 
and adhesion molecules. This greatly contributes to the ben-
eficial effects of GCs in various inflammatory diseases, because 
the endothelium is a crucial player in inflammation. However, 
the beneficial actions of GCs may sometimes be overshadowed 
by detrimental side-effects and GC resistance, in particular on 
long-term treatment. GC resistance often arises as a consequence 
of disease in otherwise GC-sensitive individuals and tissues 
and is a major problem in clinical practice. Although various 
mechanisms, including proteasomal degradation and epigenetic 
modifications, have been reported to modulate GC sensitivity of 
endothelium, it appears that the current knowledge about the 
regulation of GC sensitivity in endothelial cells is still lagging 
behind our understanding of GC-mediated effects in other cell 
types such as macrophages and dendritic cells.
As future perspectives, we believe that further studies should 
be performed to investigate the precise interactions between 
GC signaling and pro- and anti-inflammatory pathways in 
endothelial cells. Such interactions are often cell type-specific 
and differ according to the cytokines and other stimuli used 
to activate the endothelial cells in  vitro or according to the 
disease in vivo. Furthermore, exploring the regulation of GR 
activity through the variety of its isoforms and posttransla-
tional modifications and by non-coding RNAs in endothelial 
cells is highly promising. These mechanisms fine-tune the 
interactions of GR with other signaling molecules, transcrip-
tion factors, and cofactors and may dictate GC sensitivity and 
resistance. Finally, the variability of endothelial GC-mediated 
signaling between individuals and between endothelial cells 
within the body has to be addressed, since such information 
will help to define which diseases and which patient groups 
will benefit the most from GC therapy. Overall, this is a for-
midable task, but it will yield great benefits for fundamental 
science, pharmaceutical development, and precision medicine 
for patients.
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